Edesa Biotech, Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported net loss was USD 13.34 million compared to USD 6.36 million a year ago. Basic loss per share from continuing operations was USD 1.1 compared to USD 0.74 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | +1.25% | -6.08% | -3.72% |
Mar. 05 | Top Premarket Gainers | MT |
Feb. 09 | Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.72% | 13.78M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- EDSA Stock
- News Edesa Biotech, Inc.
- Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021